Novartis AG (BUE:NVS) Marketable Securities : ARS189,563 Mil (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Novartis AG Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Novartis AG's Marketable Securities for the quarter that ended in Mar. 2024 was ARS189,563 Mil.

Novartis AG's annual Marketable Securities increased from Dec. 2021 (ARS1,586,149 Mil) to Dec. 2022 (ARS1,860,580 Mil) but then declined from Dec. 2022 (ARS1,860,580 Mil) to Dec. 2023 (ARS205,409 Mil).

Novartis AG Marketable Securities Historical Data

The historical data trend for Novartis AG's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novartis AG Marketable Securities Chart

Novartis AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Marketable Securities

Get a 7-Day Free Trial

7,292.38

133,056.30

1,586,148.91

1,860,579.65

205,409.00

Novartis AG Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Marketable Securities	Get a 7-Day Free Trial															51,363.00	69,360.00	101,485.50	205,409.00	189,562.50

Novartis AG Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Novartis AG (BUE:NVS) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Novartis AG Marketable Securities Related Terms

Thank you for viewing the detailed overview of Novartis AG's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Novartis AG (BUE:NVS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novartis AG (BUE:NVS) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

NVSEF:USA NVS:USA NVS N:Mexico NOVNz:UK 0QLR:UK NOTA:Germany NOVNEE:Switzerland NOVN:Switzerland N1VS34:Brazil

Address

Lichtstrasse 35, Basel, CHE, 4056

Website

https://www.novartis.com

Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.